Hyphens Pharma International Ltd. · SGX:1J5
Hyphens Pharma International — Q1 2023 Earnings Presentation
13 slides from Hyphens Pharma International's earnings presentation, May 15, 2023
Slide 1: General Announcement: Business Update and Results Briefing 1Q 2023
5/11/23, 6:33 PM General Announcement::BUSINESS UPDATE AND RESULTS BRIEFING FOR THE FIRST QUARTER ENDED 31 MARCH 2… GENERAL ANNOUNCEMENT::BUSINESS UPDATE AND RESULTS BRIEFING FOR THE FIRST QUARTER ENDED 31 MARCH 2023 Issuer & Securities Issuer/ Manager HYPHENS PHARMA INTERNATIONAL LIMITED Securities
Slide 2: Results Briefing 1Q2023 attachment
5/11/23, 6:33 PM General Announcement::BUSINESS UPDATE AND RESULTS BRIEFING FOR THE FIRST QUARTER ENDED 31 MARCH 2… Results Briefing 1Q2023.pdf Total size =1338K MB https://links.sgx.com/1.0.0/corporate-announcements/AZJBGW1RB74EZNGN/79f1364476277d3155ff434ce98eb69587494bff25edf0cffaae93d7a… 2/2
Slide 3: Business Update for the First Quarter Ended 31 March 2023
HYPHENS PHARMA INTERNATIONAL LIMITED (Company Registration No. 201735688C) (Incorporated in the Republic of Singapore) Business Update for the First Quarter Ended 31 March 2023 The Group wishes to provide the investing community with business update for the first quarter ended 31 March 2023 (“1Q2023
Slide 4: Outlook
Outlook Growing our Proprietary Brands Proprietary Brand business remains the Group’s key focus. Hyphens’ brands, including Ocean Health®, Ceradan®, TDF® and CG 210® have enjoyed robust growth in sales and brand equity. The Group will continue to nurture these brands in markets where it already has
Slide 5: Results Briefing 1Q2023
HYPHENS PHARMA INTERNATIONAL LIMITED Results Briefing 1Q2023 15 May 2023
Slide 6: Disclaimer
DISCLAIMER This presentation has been prepared by Hyphens Pharma International Limited (the "Company" and, together with its subsidiaries, the "Group"). This content in this presentation is being furnished to you on a confidential basis and solely for your information and neither this presentation n
Slide 7: Financial Results
Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group g Hyphens
Slide 8: 1.1 Financial Performance
1.1 FINANCIAL PERFORMANCE Revenue (S$'mil) Profit After Tax (S$'mil) 42.8 41.5 4.0 39.2 38.8 33.2 3.2 3.0 1.4 1.1 1Q2022 2Q2022 3Q2022 4Q2022 1Q2023 1Q2022 2Q2022 3Q2022 4Q2022 1Q2023
Slide 9: 1.2 Financial Highlights
1.2 FINANCIAL HIGHLIGHTS S$’000 1Q2023 1Q2022 QoQ Revenue 33,234 39,168 (15.2%) Gross Profit 13,115 15,024 (12.7%) Profit before tax 1,616 4,183 (61.4%) Profit after tax 1,379 3,198 (56.9%)
Slide 10: Business Outlook
Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group g Hyphens
Slide 11: Our Growth Strategy
OUR GROWTH STRATEGY 1. Growing our proprietary brands 2. Going Digital 3. Expanding through acquisitions 4. Strengthening specialty pharma portfolio
Slide 12: Questions & Answers
Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group g Hyphens
Slide 13: Hyphens Pharma International Limited contact details
Hyphens Pharma International Limited (SGX: 1J5) 16 Tai Seng Street, Level 4, Singapore 534138 www.hyphensgroup.com
Hyphens Pharma International — Q1 2023 Earnings Presentation on 6ix